Science minister lobbies health department over AstraZeneca drug

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f368 (Published 17 January 2013)
Cite this as: BMJ 2013;346:f368

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Andrew Jack
  1. 1Financial Times

Government ministers are stepping up efforts to boost NHS prescriptions of recommended new drugs made by companies with a significant presence in the United Kingdom.

David Willetts, the science minister, has raised concerns with his counterparts at the Department of Health for England over the low adoption of new drugs that have been endorsed as safe, effective, and cost effective, including AstraZeneca’s antiplatelet drug ticagrelor (marketed as Brilique).

The action comes after growing complaints from the drug industry that doctors are ignoring positive recommendations on its drugs made by the National Institute for Health and Clinical Excellence (NICE), …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL